NEW YORK, NY, Feb. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has implemented quality assurance protocols (“QA protocols”) within the manufacturing process of its CBD Infused chewing gum (“CBD gum”); branded as Tauri-Gum TM . Each production batch of Tauri-Gum TM will be independently tested by a 3 rd party laboratory to confirm the following quality assurance standards:
- Testing for CBD label content (10mg of CBD isolate per chewing gum tablet)
- Testing the THC content (to ensure THC content of 0.00%)
- Testing to confirm that production batch is “clear” for microbiology
Tauri-Gum TM has been developed in a manner that is fully compliant with the U.S. Federal laws and regulations that govern this sector. The Company can also confirm that its CBD gum product is “Drug Test Safe” as validated by the 3 rd party laboratory testing and QA protocols.
The Company is targeting the month of March 2019 for its commercial launch of Tauri-Gum TM and is hopeful to generate revenue during this current operating quarter (its 4 th Fiscal Quarter of 2019).
ABOUT: TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. ( TAUG ) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum TM . See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com .
In addition, the Company is currently constructing an E-Commerce site for the sale of its CBD Infused Chewing Gum. This site is being constructed under the following URL address: www.taurigum.com
Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Attachment
Contact: Tauriga Sciences, Inc. 555 Madison Avenue, 5th Floor New York, NY 10022 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 www.tauriga.com
